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OCT3/4, SOX2, c-MYC and KLF4 factors. The generated cell line CSC-44 exhibits expression of common
pluripotency markers, in vitro differentiation into the three germ layers and normal karyotype. This iPSC
line can be used to explore the association between PARK2 mutations and PD.S Disease Modelin
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Mutations in the PARK2 gene are the second most common known
cause of Parkinson's disease (PD). CSC-44 iPSC line was generated
from a PD patient with a compound heterozygous mutation in PARK2.
This iPSC line can be used as a model to explore the link between mu-
tant PARK2 and PD pathology.Resource details
Mutations in PARK2 result in autosomal-recessive familial PD and
are the second most common known cause of this neurodegenera-
tive disease. PARK2 encodes for PARKIN, a E3 ubiquitin ligase that
plays a role in targeting proteins for degradation and maintaining
mitochondrial function (Nuytemans et al., 2010). Among the identi-
ﬁed PARK2 mutations, both deletions and insertions of one or more
exons and missense mutations have been described. Here, we report
the generation of an induced pluripotent stem cell line (CSC-44)
from a patient with PD caused by a compound heterozygous PARK2
mutation: point mutation c.823CNT in exon 7 and deletion of exon
6. The c.823CNT mutation in PARK2 gene predicts an arginine to
tryptophan substitution at amino acid residue 275 (p.R275W),
which is located within the RING1 domain of PARK2. This mutation
disrupts the charge distribution and leads to local rearrangements
in the RING1-IBR interface, which hampers ubiquitin ligase activity
and confers a toxic gain of function to PARKIN, leading to its aggrega-
tion (Fiesel et al., 2015; Oczkowska et al., 2013). Even though this
point mutation has been well characterized and associated with
other mutations in compound heterozygotes, its association with
the deletion of exon 6 has not been described. Given the importance
of compound heterozygous mutations on PARK2 gene, CSC-44 iPSC
line can be used to better understand the impact of both alterations
on cellular function.
To generate this line, skin ﬁbroblasts collected by punch skin
biopsy from a 78-year-old PD patient were reprogrammed using a
non-integrating Sendai virus technology. Brieﬂy, ﬁbroblasts were
seeded (75,000 cells/well) on a 12-well plate, two days before
transduction. The CytoTune™-iPS 2.0 Sendai Reprogramming Kit
was then used to deliver the four reprogramming factors (OCT3/4,
SOX2, c-MYC and KLF4). At day 7 post-transduction, the cells were
re-seeded onto mouse embryonic ﬁbroblasts (MEF)-feeder layer
and expanded until colonies presented an embryonic stem cell
(ES)-like morphology. At day 28, 12 colonies were picked and
expanded as individual clones for 7 days. Three clones (CSC-44G,
CSC-44I, CSC-44J) were further selected for expansion and karyotype
analysis. All clones were characterized using the methods we
previously described (Holmqvist et al., 2016). Here, we present the
characterization of clone CSC-44I.
The generated clone, CSC-44I, expressed the common nuclear and
cell surface pluripotency markers, OCT4/NANOG and TRA1-81/SSEA4
(Fig. 1A) and showed alkaline phosphatase (ALP) activity (Fig. 1B).
Flow cytometry analysis demonstrated that N98% of the iPSCs were
positive for SSEA4 (Fig. 1C). Additional immunocytochemistry analysis
revealed elimination of the Sendai virus at passage 7 (Fig. 1D). Fig. 1E
presents a normal female karyogram identiﬁed in CSC-44I clone. The
identity of the generated iPSC line was conﬁrmed by DNA ﬁngerprint,
showing genetic correspondence to parental ﬁbroblasts. DNA sequenc-
ing analysis of CSC-44I iPSCs conﬁrmed the presence ofmutations in the
PARK2 gene (Fig. 1F). Embryoid bodies (EBs) generated from CSC-44I
iPSCs present three-germ layer differentiation capacity as shown by
the in vitro expression of alpha-fetoprotein (AFP), an endodermal
marker, smooth muscle actin (SMA), a mesodermal marker, and beta-
III-tubulin (BIIITub), an ectodermal marker (Fig. 1G). Mycoplasma in-
fection was prevented by routine addition of plasmocin in cell culture
media at early passages.Materials and methods
Fibroblast culture
Dermal ﬁbroblasts were collected by punch skin biopsy from a
patient diagnosed with PD, after obtaining informed consent. The ﬁ-
broblasts were maintained in ﬁbroblast growth medium, composed
of DMEM media (ThermoFisher Scientiﬁc) with 10% fetal bovine
serum and 1% Penicillin-Streptomycin and passaged with 0.05%
trypsin.iPSC generation and expansion
For reprogramming, 75,000 cells were seeded on a 12-well plate and
maintained in ﬁbroblast growth medium. Two days after (day 0), the
cells were transduced using the three vector preparations (MOI = 5,
5, 3) included in the CytoTune™-iPS 2.0 Sendai Reprogramming Kit
(ThermoFisher Scientiﬁc). On the following day and on every other
day, the mediumwas replaced with fresh ﬁbroblast growthmedium.
At day 7, the cells were re-seeded onto irradiated mouse embryonic
ﬁbroblasts (MEFs) feeder cells with ﬁbroblast growth medium. On
the day after and until colony picking, the cells were cultured in
WiCell medium composed of advanced DMEM/F12 (ThermoFisher
Scientiﬁc), 20% Knock-Out Serum Replacement (v/v, ThermoFisher
Scientiﬁc), 2 mM L-glutamine (ThermoFisher Scientiﬁc), 1% non-
essential amino acids (NEAA, v/v, Millipore) and 0.1 mM β-
mercaptoethanol (Sigma-Aldrich), supplemented with 20 ng/ml
FGF2 (ThermoFisher Scientiﬁc). On day 28, individual colonies
were picked and re-seeded on a 24-well plate containing fresh
MEFs. One week after, three clones were selected based on the mor-
phology of the colonies, and further expanded on 6-well plates. The
cells were passaged once a week and seeded on the appropriate
cell culture surface for characterization assays at the indicated
passage numbers (Table 1).Immunocytochemistry
The iPSCs cultures were ﬁxed with 4% paraformaldehyde for
15 min at room temperature (RT), permeabilized and blocked for
1 h at RT with PBS containing 10% donkey serum and 0.1% TritonX-
100 (Sigma) and incubated overnight at +4 °C with the primary
antibodies (Table 2) diluted in the blocking buffer. The secondary
antibodies were thereafter added for 1 h at RT in the dark, followed
by nuclei counterstain with DAPI (1:10,000 (Life Technologies))
and image acquisition on inverted epiﬂuorescence microscope LRI -
Olympus IX-73. Scale bars are 200 μm.Alkaline phosphatase activity
Alkaline phosphatase staining was performed using Alkaline Phos-
phatase Staining Kit (Stemgent, MA).In vitro differentiation by embryoid body (EB) formation
Human iPSCs were grown for 2 weeks as embryoid bodies (EBs) in
low-attachment 24-well plates (Corning) in WiCell medium supple-
mented with 20 ng/ml FGF2. The EBs were then seeded on a 0.1%
gelatin-coated 96-well plate (Greiner Bio-One) in DMEM media
containing 10% fetal bovine serum and 1% Penicillin-Streptomycin for
subsequent spontaneous differentiation, with media changes every
2–3 days. After 2 weeks, the cells were ﬁxed and stained for three
germ-layer markers as described in Table 2.
Fig. 1. Characterization of the iPSC line CSC-44I.
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Table 1
Characterization and validation.
Classiﬁcation Test Result Data
Morphology Photography Visual record of the line: normal Not shown but available with author
Phenotype Immunocytochemisty Positive staining for pluripotency markers: OCT4,
NANOG, TRA1-81 and SSEA4
Fig. 1 panel A
Alkaline phosphatase activity Visible activity Fig. 1 panel B
Flow cytometry 94.8% SSEA4 Fig. 1 panel C
Karyotype G-banding 46,XX, (300–400 bands resolution in average) Fig. 1 panel E
Identity STR analysis 10 sites analyzed, all matched with parent
ﬁbroblast cell line
Available with author
Mutation analysis (IF APPLICABLE) Sequencing Compound heterozygous mutation in the PARK2
gene (c.823CNT and EX6del)
Fig. 1 panel F
Microbiology and virology Mycoplasma Mycoplasma testing by RT-PCR. Negative. Not shown but available with author
Differentiation potential Embryoid body formation Staining of smooth muscle actin, beta-III-tubulin
and alpha-fetoprotein after spontaneous
differentiation of embryoid bodies
Fig. 1 panel G
Donor screening (OPTIONAL) HIV 1 + 2 Hepatitis B, Hepatitis C N/A N/A
Genotype additional info (OPTIONAL) Blood group genotyping N/A N/A
HLA tissue typing N/A N/A
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The G-banding analysis was performed at 300–400 band resolution
in average after 9 passages, at the Department of Clinical Genetics and
Pathology in Lund.
Mutation sequencing
Genomic DNA from ﬁbroblasts and iPSCs was extracted using con-
ventional lysis buffer composed of 100 mM Tris (pH 8.0), 200 mM
NaCl, 5 mM EDTA and 0.2% SDS in distilled autoclaved water supple-
mented with 1.5 mg/ml Proteinase K. The mutation in the PARK2 gene
was conﬁrmed by direct DNA sequencing (Macrogen Europe,
Amsterdam, The Netherlands). Primers used for ampliﬁcation and di-
rected sequencing of PARK2 around the mutation sites are listed in
Table 2.
DNA ﬁngerprinting
Genomic DNA from ﬁbroblasts and iPSCs was isolated as described
above and ﬁngerprinting analyses was outsourced to the IdentiCell
STR proﬁling service (Department of Molecular Medicine, Aarhus Uni-
versity Hospital, Skejby, Denmark).Table 2
Reagents details.
Antibodies used for immunocytochemistry
Antibody Dil
Pluripotency markers Mouse anti-Oct4 1:2
PE-conjugated mouse anti-human NANOG 1:2
Mouse anti- TRA-1-81 1:2
PE-conjugated mouse anti-SSEA4 1:2
Sendai Chicken anti-Sendai virus 1:1
Differentiation markers Mouse anti-AFP 1:2
Mouse anti-SMA 1:2
Mouse anti-beta-III tubulin 1:2
Secondary antibodies Donkey anti-mouse Alexa Fluor® 488 1:4
Donkey anti-chicken Alexa Fluor® 488 1:4
Donkey anti-mouse Alexa Fluor® 555 1:4
Primers
Target
Mutation sequencing PARK2Mycoplasma detection
Absence of mycoplasma contamination was conﬁrmed by the real-
time PCRmethod at GATC Biotech AG (European Genome and Diagnos-
tics Centre, Konstanz, Germany).
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Forward/reverse primer (5′-3′)
AGGATTACAGAAATTGGTCT/TCTGTTCTTCATTAGCATTAGA
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